
Rivastina 1.5mg Capsule
Marketer
Cortina Laboratories Pvt Ltd
Salt Composition
Rivastigmine (1.5mg)
Overview Rivastina 1.5mg Capsule
Alzex 1.5mg capsules are indicated for managing mild to moderate Alzheimer's dementia, a degenerative condition impacting cognitive function and memory. This medication also offers symptomatic relief for Parkinson's disease-related dementia. While not a cure, Alzex 1.5mg may enhance memory, alertness, and other associated symptoms. Your physician will provide detailed administration instructions; adhere closely to the prescribed regimen for optimal results. Dosage adjustments may be necessary based on individual response. The medication can be taken with food, ideally before bedtime. Symptom improvement may take several weeks; consistent use is crucial. Discontinuation should only occur under medical supervision. Common adverse effects include nausea, vomiting, weight loss, dyspepsia, and fatigue. These reactions may be more frequent initially or following dose increases, typically subsiding with continued use. Severe or persistent side effects warrant immediate medical attention. Prior to commencing Alzex 1.5mg, inform your doctor of any history of cardiac issues, peptic ulcers, seizures, or respiratory conditions like asthma. Potential drug interactions exist; disclose all current medications to ensure safety. Use during pregnancy is only justified under strict medical guidance.
Primary Ingredients of Rivastina 1.5mg Capsule
No text provided. Please provide the text you wish me to rephrase.
Uses of Rivastina 1.5mg Capsule
Managing dementia in Parkinson's and Alzheimer's disease
Major Benefits of Rivastina 1.5mg Capsule:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Consume the Rivastina 1.5mg Capsule with a meal.
Common Side effects of Rivastina 1.5mg Capsule:
- Loss of appetite
- Nausea
- Vomiting
- Indigestion
How to use Rivastina 1.5mg Capsule:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Consume the 1.5mg Rivastina capsule with food.
How Rivastina 1.5mg Capsule works:
Cognitive decline characteristic of Alzheimer's results from impaired neuronal communication. Rivastina 1.5mg Capsules act as a cholinesterase inhibitor, boosting acetylcholine—a neurotransmitter crucial for nerve signaling—thereby enhancing cognitive function and memory.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The interaction between Rivastina 1.5mg Capsule and alcohol is undetermined. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Use of Rivastina 1.5mg capsules is contraindicated in pregnancy due to established risk to the fetus. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is essential.
Breast feedingCONSULT YOUR DOCTOR
Breastfeeding while taking Rivastina 1.5mg capsules is likely inadvisable. Available data in humans indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Taking a 1.5mg Rivastina capsule could reduce alertness, impair vision, and cause drowsiness or dizziness. Driving should be avoided if these effects are experienced.
KidneySAFE IF PRESCRIBED
Patients with kidney disease can safely use Rivastina 1.5mg capsules without a recommended dosage change. Nevertheless, disclosure of pre-existing kidney conditions to your physician is crucial, as careful monitoring during treatment is advisable.
LiverSAFE IF PRESCRIBED
Patients with liver conditions can safely use Rivastina 1.5mg capsules without needing a dosage change. Nevertheless, disclosure of pre-existing liver disease to your physician is crucial, as careful observation during treatment is recommended.
What if you forget to take Rivastina 1.5mg Capsule :
Omit any missed Rivastina 1.5mg Capsule dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Rivastina 1.5mg Capsule
| Label | Value |
|---|---|
| Chemical Category | Carbamate-based compound |
| Developing Habits | No. |
| Type of Therapy | Neuroscience of the Central Nervous System |
